Corcept Therapeutics reported $225.75M in Operating Expenses for its fiscal quarter ending in September of 2026.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 270.57M 450K Sep/2026
Alaunos Therapeutics USD 952K 60K Jun/2026
ANI Pharmaceuticals USD 637.11M 39.9M Sep/2026
Ardelyx USD 133.3M 6.04M Jun/2026
Aurora Cannabis CAD 76.28M 28.24M Jun/2026
BioMarin Pharmaceutical USD 819.04M 5.5B Sep/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Canopy Growth CAD 98.74M 23K Jun/2026
Corcept Therapeutics USD 225.75M 10.9M Sep/2026
Eli Lilly USD 10.52B 496M Jun/2026
J&J USD 18.93B 1.09B Sep/2026
Knight Therapeutics CAD 126.9M 8.29M Dec/2025
Lexicon Pharmaceuticals USD 20.27M 6.1M Dec/2025
Merck USD 10.75B 5.02B Sep/2026
Nektar Therapeutics USD 49.12M 8.22M Mar/2026
Novartis USD 9.88B 325M Sep/2026
Novartis USD 13.19B 3.9B Sep/2026
Omeros USD 59.16M 20.13M Jun/2024
Pacira USD 1.18B 995.96M Sep/2026
Pfizer USD 89B 3.81B Sep/2026
Supernus Pharmaceuticals USD 1.06B 31.25M Sep/2026
TG Therapeutics USD 174.04M 44.62M Sep/2026